This article was originally published in The Tan Sheet
FY 2000 net income of $5.1 mil., attributable to a $16.3 mil. recovery in vitamin price-fixing litigation, compares favorably to $7 mil. net loss in prior year, supplement maker says in Oct. 27 announcement of results for fourth quarter and year ended July 31. Quarterly and annual sales fell approximately 20% to $17.6 mil. and $85.9 mil., respectively. Freehold, N.J.-based firm attributes declines to cancellation of certain sales contracts due to inadequate margins, discontinued items at a major account, divestiture of the Vitamin Specialties retail unit and industry-wide softness in some segments. Separately, IVC reached a $30.5 mil. credit facility with First Union National Bank subsidiary Congress Financial
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC